Biodexa Pharmaceuticals Files May 2025 6-K Report
Ticker: BDRX · Form: 6-K · Filed: May 30, 2025 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | May 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, corporate-information, foreign-issuer
TL;DR
Biodexa (formerly Midatech) filed its May 6-K, standard foreign issuer update.
AI Summary
Biodexa Pharmaceuticals Plc filed a Form 6-K on May 30, 2025, reporting for the month of May 2025. The company, formerly known as Midatech Pharma Plc, is a foreign private issuer and files annual reports under Form 20-F. Its principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Why It Matters
This filing provides routine updates for investors regarding Biodexa Pharmaceuticals Plc's reporting status and corporate information as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing providing corporate information and not announcing significant financial or operational changes.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- May 30, 2025 (date) — Filing date
- 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom (location) — Principal executive office address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
When was Biodexa Pharmaceuticals Plc previously known by another name?
Biodexa Pharmaceuticals Plc was formerly known as Midatech Pharma Plc, with a date of name change on June 2, 2015.
Does Biodexa Pharmaceuticals Plc file annual reports under Form 20-F?
Yes, the filing indicates by check mark that the registrant files annual reports under cover of Form 20-F.
What is the principal executive office address for Biodexa Pharmaceuticals Plc?
The principal executive office is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
What is the SIC code for Biodexa Pharmaceuticals Plc?
The Standard Industrial Classification (SIC) code for Biodexa Pharmaceuticals Plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 30, 2025 regarding Biodexa Pharmaceuticals Plc (BDRX).